RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.

摘要: 11509Background: RAS mutational status is required to prescribe anti-EGFR antibodies in mCRC. In comparison molecular testing from tumor tissue, the characterization of mutations ctDNA a promising and credible way shorten workflow. This study reports for first time performance plasma large prospective series. Methods: Blood samples were prospectively collected before 1st line chemotherapy mCRC patients. was centrally assessed by NGS using colon lung cancer V2 Ampliseq panel methylation digital PCR assay (WIF or NPY). Tumor tissue done according routine practice each center. We expect minimal kappa coefficient 0.7 reflect concordance. order have precision ± 0.07 with an estimated 5% non-exploitable data 425 pts had be included. Results analyzed separately whole population subgroup evidenced either presence at least 1 mutation ...